/XOMA
XOMA Stock - XOMA Royalty Corp.
Healthcare|BiotechnologyNASDAQ
$25.39+1.97%
+$0.49 (+1.97%) • Dec 19
67
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.24
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.82
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+163.9%upside
Target: $67.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for XOMA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$25.14 – $25.64
TARGET (TP)$67.00
STOP LOSS$23.36
RISK/REWARD1:20.5
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.94
52W High$39.92
52W Low$18.35
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $28.49M | $4.76M | $6.03M | $38.16M | $29.39M |
| Gross Profit | $28.28M | $4.62M | $5.75M | $37.99M | $29.21M |
| Gross Margin | 99.3% | 97.0% | 95.5% | 99.6% | 99.4% |
| Operating Income | $-39,976,000 | $-41,848,000 | $-17,414,000 | $17.53M | $12.42M |
| Net Income | $-13,821,000 | $-40,831,000 | $-17,104,000 | $15.80M | $13.30M |
| Net Margin | -48.5% | -858.2% | -283.8% | 41.4% | 45.3% |
| EPS | $-1.65 | $-4.04 | $-1.98 | $0.69 | $0.82 |
Company Overview
XOMA Royalty Corp. operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
2 Bullish0 Neutral/Bearish
Price Targets
$38
Average Target
↑ 47.7% Upside
Now
$35
Low
$38
Average
$40
High
Based on 2 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| April 17th 2025 | The Benchmark Company | Initiation | Buy | $35 |
| April 29th 2024 | Leerink Partners | Initiation | Outperform | $40 |
Earnings History & Surprises
XOMABeat Rate
28%
Last 18 quarters
Avg Surprise
-138.6%
EPS vs Estimate
Beats / Misses
5/13
Last 12 quarters
Latest EPS
$-0.35
Q4 2025
EPS Surprise History
Q1 24
-36.1%
$-0.49vs$-0.36
Q2 24
-21.1%
$-0.86vs$-0.71
Q3 24
-7.7%
$-0.28vs$-0.26
Q4 24
+11.4%
$-0.39vs$-0.44
Q1 25
-58.6%
$-0.46vs$-0.29
Q2 25
+123.1%
$0.06vs$-0.26
Q3 25
+500.0%
$0.48vs$-0.12
Q4 25
-1650.0%
$-0.35vs$-0.02
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 16, 2026 | $-0.04 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.02 | $-0.35 | -1650.0% | ✗ MISS |
Q3 2025 | Aug 13, 2025 | $-0.12 | $0.48 | +500.0% | ✓ BEAT |
Q2 2025 | May 13, 2025 | $-0.26 | $0.06 | +123.1% | ✓ BEAT |
Q1 2025 | Mar 17, 2025 | $-0.29 | $-0.46 | -58.6% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $-0.44 | $-0.39 | +11.4% | ✓ BEAT |
Q3 2024 | Aug 13, 2024 | $-0.26 | $-0.28 | -7.7% | ✗ MISS |
Q2 2024 | May 9, 2024 | $-0.71 | $-0.86 | -21.1% | ✗ MISS |
Q1 2024 | Mar 8, 2024 | $-0.36 | $-0.49 | -36.1% | ✗ MISS |
Q4 2023 | Nov 7, 2023 | $-0.48 | $-0.60 | -25.0% | ✗ MISS |
Q3 2023 | Aug 8, 2023 | $-0.52 | $-0.59 | -13.5% | ✗ MISS |
Q2 2023 | May 9, 2023 | $-0.50 | $-0.98 | -96.0% | ✗ MISS |
Q1 2023 | Mar 9, 2023 | $0.47 | $-0.64 | -236.2% | ✗ MISS |
Q4 2022 | Nov 3, 2022 | $-0.20 | $-0.48 | -140.0% | ✗ MISS |
Q3 2022 | Aug 4, 2022 | $-0.11 | $-0.53 | -381.8% | ✗ MISS |
Q2 2022 | May 5, 2022 | $-0.34 | $-0.32 | +5.9% | ✓ BEAT |
Q1 2022 | Mar 8, 2022 | $2.27 | $1.67 | -26.4% | ✗ MISS |
Q4 2021 | Nov 4, 2021 | $-0.09 | $-0.51 | -466.7% | ✗ MISS |
Q3 2021 | Aug 5, 2021 | $-0.41 | $-0.31 | +24.4% | ✓ BEAT |
Latest News
HC Wainwright & Co. Maintains Buy on XOMA Royalty, Lowers Price Target to $97
📈 PositiveBenzinga•Dec 11, 2025, 06:53 PM
Leerink Partners Maintains Outperform on XOMA Royalty, Lowers Price Target to $45
➖ NeutralBenzinga•Dec 11, 2025, 05:38 PM
UPDATE: XOMA Q3 Adj. EPS $(0.29) Misses $(0.04) Estimate, Adj.
📉 NegativeBenzinga•Nov 12, 2025, 07:59 PM
XOMA Q3 EPS $0.70 May Not Be Comparable To $(0.04) Estimate, Sales $9.351M Miss $11.467M Estimate
📉 NegativeBenzinga•Nov 12, 2025, 12:37 PM
XOMA Royalty May Offer & Sell Shares Of Common Stock From Time To Time Of Up To $75M
➖ NeutralBenzinga•Oct 3, 2025, 09:51 PM
Frequently Asked Questions about XOMA
What is XOMA's current stock price?
XOMA Royalty Corp. (XOMA) is currently trading at $25.39 per share. The stock has moved +1.97% today.
What is the analyst price target for XOMA?
The average analyst price target for XOMA is $67.00, based on 1 analyst.
What sector is XOMA Royalty Corp. in?
XOMA Royalty Corp. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is XOMA's market cap?
XOMA Royalty Corp. has a market capitalization of $0.30 billion, making it a small-cap company.
Does XOMA pay dividends?
No, XOMA Royalty Corp. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAURA
Aura Biosciences, Inc.
$5.86
Mkt Cap: $0.4B
AUTL
Autolus Therapeutics plc
$1.63
Mkt Cap: $0.4B
BNTC
Benitec Biopharma Inc.
$11.50
Mkt Cap: $0.3B
DMAC
DiaMedica Therapeutics Inc.
$8.48
Mkt Cap: $0.4B
DSGN
Design Therapeutics, Inc.
$9.68
Mkt Cap: $0.6B
GALT
Galectin Therapeutics Inc.
$4.38
Mkt Cap: $0.3B
IMAB
I-Mab
$3.95
Mkt Cap: $0.3B
QSI
Quantum-Si incorporated
$1.27
Mkt Cap: $0.2B
RCKT
Rocket Pharmaceuticals, Inc.
$3.23
Mkt Cap: $0.3B
SLDB
Solid Biosciences Inc.
$5.94
Mkt Cap: $0.5B
Explore stocks similar to XOMA for comparison